Abstract
Objective: To study the comparative effect of enalapril, moexipril and fozinopril on the level of blood pressure, course of the menopausal syndrome and characteristics of bone tissue density in women with arterial hypertension in postmenopause. Design and Methods: 106 women participated in the study; they were divided into 3 comparable groups based on the antihypertensive therapy. The average age of the women was 53.7 ± 1.23 years. Postmenopausal period duration was 3,93 ± 0,67 years. To examine the impact on the course of hypertension, osteoporosis, pathological menopausal syndrome before treatment and after 1, 3, 6 and 12 months of therapy, the dynamics of blood pressure was evaluated with the help of traditional sphygmomanometer during monitoring visits. Before the start of the study and after 12 months, the bone mineral density was determined by DEXA (lumbar spine). Intensity of the menopausal syndrome was assessed with the help of a questionnaire. Results: Against the background of treatment by enalapril, moexipril and fozinopril, significant reduction in systolic blood pressure was identified within 18–24 days and in diastolic blood pressure closer to the end of the 3rd month. Antihypertensive effect was comparable in all the groups and remained stable throughout the period of observation. Only the group of patients using moexipril demonstrated significant improvement of bone mineral density compared with the group of patients using enalapril (p < 0,05) and fozinopril (p > 0,05), as well as in comparison with the control group (p < 0.01). Moexipril treatment led to a significant decrease of the severity of climacteric disorders in 84.7% and to an improvement of the mental condition. 67.2% of women using fozinoprilom therapy showed reduction of climacteric symptoms without any influence on their mental status. Enalapril had no effect on the psycho-emotional and vegetative disorders. Conclusion. Moexipril is the drug of choice in the treatment of arterial hypertension in postmenopausal women, as it has a positive effect on bone mass and menopausal disorders.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have